Chimerix ROA 2011-2018 | CMRX

Current and historical return on assets (ROA) values for Chimerix (CMRX) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Chimerix ROA for the three months ending June 30, 2018 was -33.33%.
Chimerix Annual ROA
2017 -30.18
2016 -26.64
2015 -32.97
2014 -20.32
2013 -32.14
2012 -13.76
2011 -100.62
2010 0.00
Chimerix Quarterly ROA
Q2 2018 -9.26
Q1 2018 -9.23
Q4 2017 -8.18
Q3 2017 -7.04
Q2 2017 -6.47
Q1 2017 -6.52
Q4 2016 -5.22
Q3 2016 -5.73
Q2 2016 -5.84
Q1 2016 -8.10
Q4 2015 -10.63
Q3 2015 -8.29
Q2 2015 -5.89
Q1 2015 -8.12
Q4 2014 -6.94
Q3 2014 -8.74
Q2 2014 -5.73
Q1 2014 -10.16
Q4 2013 -7.21
Q3 2013 -5.58
Q2 2013 -9.85
Q1 2013 -34.58
Q4 2012 -13.51
Q3 2012 0.00
Q2 2012 0.00
Q1 2012 0.00
Q4 2011 0.00
Q4 2010 0.00
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.183B $0.004B
Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $130.270B 19.97
Abbott Laboratories (ABT) United States $120.171B 25.18
Stryker (SYK) United States $64.899B 25.08
Boston Scientific (BSX) United States $51.846B 26.97
Baxter (BAX) United States $41.480B 28.23
Zimmer Biomet Holdings (ZBH) United States $26.421B 16.97
Smith & Nephew SNATS (SNN) United Kingdom $16.200B 0.00
ResMed (RMD) United States $16.068B 31.90
Canopy Growth (CGC) Canada $11.278B 0.00
Perrigo (PRGO) Ireland $10.034B 14.24
Bio-Rad Laboratories (BIO) United States $8.905B 57.18
Hill-Rom Holdings (HRC) United States $6.097B 20.68
Insulet (PODD) United States $6.090B 0.00
Haemonetics (HAE) United States $5.674B 51.78
ICU Medical (ICUI) United States $5.462B 37.01
Neogen (NEOG) United States $4.728B 75.23
GW Pharmaceuticals (GWPH) United Kingdom $4.267B 0.00
Agios Pharmaceuticals (AGIO) United States $4.204B 0.00
Hutchison China MediTech (HCM) China $3.776B 0.00
NuVasive (NUVA) United States $3.601B 34.16
National Vision Holdings (EYE) United States $3.257B 71.93
Quidel (QDEL) United States $2.673B 54.77
NxStage Medical (NXTM) United States $1.849B 0.00
Phibro Animal Health (PAHC) United States $1.722B 24.51
Cardiovascular Systems (CSII) United States $1.264B 754.60
AtriCure (ATRC) United States $1.253B 0.00
VAREX IMAGING (VREX) United States $1.144B 18.69
Omeros (OMER) United States $1.141B 0.00
Owens & Minor (OMI) United States $1.069B 11.43
PetIQ (PETQ) United States $1.026B 33.57
Eagle Pharmaceuticals (EGRX) United States $1.019B 30.08
Surmodics (SRDX) United States $1.000B 120.81
Cerus (CERS) United States $0.978B 0.00
MacroGenics (MGNX) United States $0.966B 0.00
OraSure Technologies (OSUR) United States $0.949B 62.08
TG Therapeutics (TGTX) United States $0.741B 0.00
LeMaitre Vascular (LMAT) United States $0.678B 32.50
Insys Therapeutics (INSY) United States $0.676B 0.00
Meridian Bioscience (VIVO) United States $0.634B 21.67
Lantheus Holdings (LNTH) United States $0.617B 19.17
NanoString Technologies (NSTG) United States $0.506B 0.00
Evolus (EOLS) United States $0.504B 0.00
Quanterix (QTRX) United States $0.412B 0.00
Cytosorbents (CTSO) United States $0.407B 0.00
Utah Medical Products (UTMD) United States $0.353B 22.73
Surface Oncology (SURF) United States $0.320B 0.00
BioLife Solutions (BLFS) United States $0.286B 0.00
Bovie Medical (BVX) United States $0.241B 0.00
Rockwell Medical (RMTI) United States $0.217B 0.00
Fonar (FONR) United States $0.156B 7.76
Conatus Pharmaceuticals (CNAT) United States $0.142B 0.00
Chembio Diagnostics (CEMI) United States $0.136B 0.00
Female Health (VERU) United States $0.100B 0.00
Oramed Pharmaceuticals (ORMP) Israel $0.082B 0.00
Trinity Biotech (TRIB) Ireland $0.081B 24.13
United-Guardian (UG) United States $0.077B 16.87
Neurotrope (NTRP) United States $0.068B 0.00
InfuSystems Holdings (INFU) United States $0.065B 0.00
Imprimis Pharmaceuticals (IMMY) United States $0.060B 0.00
CAS Medical Systems (CASM) United States $0.057B 0.00
ImmuCell (ICCC) United States $0.042B 0.00
Capricor Therapeutics (CAPR) United States $0.034B 0.00
Myomo (MYO) United States $0.027B 0.00
Valeritas Holdings (VLRX) United States $0.024B 0.00
Akers Biosciences Inc (AKER) United States $0.023B 0.00
Senestech (SNES) United States $0.016B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.015B 0.00
NeuroMetrix (NURO) United States $0.010B 0.00
Cellectar Biosciences (CLRB) United States $0.009B 0.00